Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05503797 |
| Consolidated Lead Sponsor | Fore Biotherapeutics |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 254 participants (ESTIMATED) |
| Registered Start Date | 2023-02-21 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | Open Hospital Dossier -> |
| Tufts Medical Center | Boston, MA | Open Hospital Dossier -> |
| Massachusetts General Hospital | Boston, MA | Open Hospital Dossier -> |
| Dana-Farber Cancer Institute | Boston, MA | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.